|
Sign In to gain access to subscriptions and/or personal tools.
|
Pharmacology and Safety Assessment of Humanized Monoclonal Antibodies for Therapeutic Use
Corine Klingbeil
Preclinical Development Department, Protein Design Labs, Inc., Fremont, California 94555, cklingbe{at}pdl.com.
Di-Hwei Hsu
Preclinical Development Department, Protein Design Labs, Inc., Fremont, California 94555
The humanization of monoclonal antibodies has generated a class of therapeutic products with improved safety, longer half-lives, and greatly diminished immunogenicity. These engineered proteins are highly species specific and in many cases only cross-react in humans. Where there is cross-reactivity in nonhuman primates or other species, it is not always clear that the pharmacologic effects reflect the potential actions in human volunteers or patients. As with other biologic products, the profile of humanized monoclonal antibodies dictates the preclinical strategy. The preclinical programs for the 2 humanized monoclonal antibodies described here, anti-HLA-DR (Hu1D10) and anti-CD3 (HuM291), demonstrate several unique aspects that affected their preclinical development strategy. Hu1D10 binds to a posttranslational form of HLA-DR and recognizes this antigen in some but not all human and nonhuman primates. The second antibody, HuM291, cross-reacts with CD3 only in the chimpanzee, which is not an optimal test species. In addition, a marketed anti-CD3 product exists (OKT3®), and in the preclinical development of our antibody during testing of efficacy and safety, we needed to focus on adverse effects that might be similar to those of OKT3®. In these studies, the safety, pharmacokinetics, immunogenicity, and pharmacology (B- and T-cell depletion and recovery) of the 2 antibodies were evaluated. The focus in this review is on the safety and pharmacology testing and the current status of each drug.
Key Words: B cell • T cell • chimpanzee • anti-HLA-DR • anti-CD3 • immunogenicity • IgG2 • cytokine release syndrome • CRS
References
- Abramowicz D., Schandene L., Goldman M., Crusiaux A., Vereerstraeten P., De Pauw L., Wybran J., Kinnaert P., Dupont E., and Toussaint C. (1989). Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47: 606.[Web of Science][Medline]
[Order article via Infotrieve]
- Cole MS, Anasetti C., and Tso JY (1997). Human IgG2 variants of chimeric anti-CD3 are non-mitogenic to T cells. J. Immunol. 159: 3613-3621.[Abstract]
- Goldstein G., Fuccello AJ, Norman DJ, Schield CF, Colvin RB, and Cosimi AB (1986). OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies. Transplantation 42: 507-511.[Web of Science][Medline]
[Order article via Infotrieve]
- Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P., Garovoy M., O'Connell JB, Stuart F., McDiarmid SV, and Wall W. (1995). The OKT3 antibody response study: A multicentre study of human antimouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transplant. Immunol. 3: 212.[CrossRef][Medline]
[Order article via Infotrieve]
- Maloney DG, Grillo-López AJ, White CA, Bodkin D., Schilder RJ, Neidhart JA, Janakiraman N.,Foon KA, Liles TM, Dallaire BK, Wey K., Royston I., Davis T., and Levy R. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.[Abstract/Free Full Text]
- Sgro C. (1995). Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: Bibliographic review. Toxicology 105: 23-29.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Toxicologic Pathology, Vol. 27, No. 1,
1-3 (1999)
DOI: 10.1177/019262339902700101
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. J. Horvath and M. N. Milton
The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?
Toxicol Pathol,
April 1, 2009;
37(3):
372 - 383.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tawara, K. Hasegawa, Y. Sugiura, K. Harada, T. Miura, S. Hayashi, T. Tahara, M. Ishikawa, H. Yoshida, K. Kubo, et al.
Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats
J. Immunol.,
February 15, 2008;
180(4):
2294 - 2298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
